Full Press Release Details
Bio Appeals NASDAQ Delisting Notice;
Granted and Scheduled for October 20, 2022
PA, September 19, 2022 - AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we")
(ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced
that on September 16, 2022, the Company filed a request for a hearing before the NASDAQ Hearings Panel to present its financial
data including Shareholders' Equity and plan with the applicable listing requirements. This request was due to a Staff determination
letter (the "Letter") on September 9, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq")
notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Capital Market
due to the Company's failure to regain compliance with the $1 per share bid price requirement of Listed Securities required for
continued listing as set forth in Listing Rule 5450(a)(1) (the "$1 Bid Rule"), following the 180 calendar day compliance
period set forth in Listing Rule 5810(c)(3)(A) (the "Compliance Period"). On September
16, 2022, Company received a letter from Nasdaq granting the appeal and scheduling the Nasdaq Hearings Panel for October 20, 2022.
In the meantime, the Company will continue to be listed and its shares will continue to be traded on Nasdaq, pending a final written
decision by the Nasdaq Hearings Panel after the October 20, 2022 hearing.
9, 2022, the Company received a Staff determination letter (the "Letter") from the Listing Qualifications Department of The
Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination to delist the Company's
securities from The Nasdaq Capital Market due to its failure to regain compliance with the $1 Bid Rule within the 180 calendar day Compliance
Period. Earlier, on March 8, 2022, Nasdaq staff notified the Company that the bid price of its listed security had closed at less than
$1 per share over the previous 30 consecutive business days, and, as a result, did not comply with the $1 Bid Rule. In accordance with
Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until September 5, 2022, to regain compliance with the $1
Bid Rule. Since then, the Company has not regained compliance with the $1 Bid Rule, and Nasdaq staff believes that the Company is not
eligible for a second 180 day Compliance Period because Nasdaq staff believes that the Company has not demonstrated compliance with the
minimum $5,000,000 Shareholders' Equity initial listing requirement for The Nasdaq Capital Market. Nasdaq had written to the Company
earlier that if Company has a Shareholders' Equity above $5,000,000, it may obtain another 180 day period.
At the October 20, 2022 hearing, the Company
intends to present its financial data including Shareholders' Equity and its plan (including share reverse split) to regain compliance
with $1 Bid Rule to seek a second 180 day period. There can be no assurance that the Panel will grant the Company's request for
a suspension of delisting or continued listing, even if the Company's financial data evidences sufficient Shareholders' Equity.
AnPac Bio is a biotechnology company focused
on early cancer screening and detection, with 155 issued patents as of March 31, 2022. With two certified clinical laboratories in China
and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection
tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to a report by Frost
& Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection test sample volume (accumulative to January 2021).
AnPac Bio's CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20
different cancer types with high sensitivity and specificity.
investor and media inquiries, please contact:
Case, Marketing and Investor Relations
+1-267-810-6776 (US)
Email: phil_case@AnPacbio.com
Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company
has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates,"
"expects," "plans," "projects," "intends," "potential," "target,"
"aim," "predict," "outlook," "seek," "goal" "objective," "assume,"
"contemplate," "continue," "positioned," "forecast," "likely," "may,"
"could," "might," "will," "should," "approximately" or other words that convey
uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations,
assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future
business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control.
These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results
to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and
other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules, the implementation of our business model
and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and
market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and
maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology
developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our
laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results
of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and
business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business
partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and
financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines
and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally,
all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent
Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties
and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as
of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly
any forward-looking statements for any reason.